BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AMP Reports on Possibilities, Challenges, and Applications of Next-Generation Sequencing


10/19/2012 10:09:39 AM

BETHESDA, Md., Oct. 18, 2012 /PRNewswire-USNewswire/ -- The Association for Molecular Pathology (AMP) published the report of the Whole Genome Analysis (WGA) Working Group of the AMP Clinical Practice Committee in the November 2012 issue of The Journal of Molecular Diagnostics (JMD). Titled "Opportunities and Challenges Associated with Clinical Diagnostic Genome Sequencing," the timely report provides a detailed and compelling overview of the landscape of next generation sequencing (NGS) technology and its clinical relevance and impact on improving patient care. The issues addressed in the report are comprehensive, including " ... current technical, bioinformatic, and clinical implementation considerations, as well as medical applications, clinical utility, and ethical, legal, and education issues presented by genome-level diagnostic testing."(1)

NGS-related technologies and instrumentation introduced over the past decade have significantly alleviated the amount of resources required to conduct complex genomic analysis. "The possibilities of these technologies are numerous," noted Iris Schrijver, AMP President and lead author of the report. "As the only Association whose members are experts specifically dedicated to the field of molecular pathology, AMP has the responsibility to initiate and lead the discussion on safe, effective and practical applications of next-generation sequencing."

The report illuminates the current state of NGS by calling out and highlighting the issues to be addressed in greater depth moving forward. "The next phase of reporting will include detailed studies of the validation, interpretation, and bioinformatics elements of NGS. We are excited to collaborate with other organizations to develop guidelines for application and quality assessment," said Jane Gibson, WGA Working Group Chair. "While this report is comprehensive, there is much yet to be done."

A full copy of the report is available online at: http://bit.ly/QVQSqt

ABOUT AMP:
The Association for Molecular Pathology (AMP) is an international medical professional association dedicated to the advancement, practice, and science of clinical molecular laboratory medicine and translational research based on the applications of molecular biology, genetics, and genomics. The Annual Meeting will be held in Long Beach, CA, October 25-27, 2012. For more information, please visit www.amp.org.

CONTACT:
Mary Steele Williams
mwilliams@amp.org
(301) 634-7921

(1) Schrijver, I, et al: Opportunities and Clinical Challenges Associated with Clinical Diagnostic Genome Sequencing. The Journal of Molecular Diagnostics 2012, 14: 541-549.

SOURCE Association for Molecular Pathology



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES